Longitudinal monitoring of response to chemotherapy in patients with malignant pleural mesothelioma by biomarkers.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2023-01-01 DOI:10.3233/CBM-220436

Filiz Bogar, Guntulu Ak, Selma Metintas, Adnan Ayhanci, Muzaffer Metintas

{"title":"Longitudinal monitoring of response to chemotherapy in patients with malignant pleural mesothelioma by biomarkers.","authors":"Filiz Bogar, Guntulu Ak, Selma Metintas, Adnan Ayhanci, Muzaffer Metintas","doi":"10.3233/CBM-220436","DOIUrl":null,"url":null,"abstract":"Background: The aim of the study was to longitudinally investigate the serum levels of mesothelin, sestrin1, hyaluronan synthase 2 (HAS2), midkine, and high mobility group box 1 (HMGB1) before and after chemotherapy and at the time of relapse in malignant pleural mesothelioma (MPM) patients treated with chemotherapy and to compare the changes in biomarker levels with radiological treatment outcome.Methods: A total of 64 MPM patients treated with chemotherapy were enrolled in the study and longitudinally followed for changes in biomarker levels in response to treatment. Biomarkers levels were measured in serum using a human ELISA kit. Relative and absolute changes in biomarker levels were compared with the best radiological overall response at each time point.Results: Median survival was 20.0 ± 2.4 (15.3-24.7) months in patients with partial and complete response, 17.0 ± 1.0 (15.0-19.0) months in patients with stable disease, and 9.0 ± 1.0 (7.0-11.0) months in patients with progressive disease. A significant decrease in serum levels of mesothelin, midkine, and HMGB1 was observed in patients with radiologically partial and complete responses to chemotherapy (p< 0.001, p= 0.016, and p= 0.039, respectively). In these patients, mesothelin levels decreased by 15%, midkine levels by 7%, and HMGB1 levels by 15%. In addition, HMGB1 serum levels were found to significantly increase by 15% in patients with radiologically progressive responses to chemotherapy compared to pretreatment serum levels (p= 0.035). In patients with partial and complete response to chemotherapy, mesothelin levels increased by 15%, midkine by 12%, and sestrin1 by 8% when the disease recurred (p= 0.004, p= 0.004 and p= 0.044, respectively).Conclusion: Biomarkers may be useful in the longitudinal monitoring of response to treatment in MPM. However, the results of our study should be validated in larger groups with sufficient case numbers from multicenter institutions.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3233/CBM-220436","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The aim of the study was to longitudinally investigate the serum levels of mesothelin, sestrin1, hyaluronan synthase 2 (HAS2), midkine, and high mobility group box 1 (HMGB1) before and after chemotherapy and at the time of relapse in malignant pleural mesothelioma (MPM) patients treated with chemotherapy and to compare the changes in biomarker levels with radiological treatment outcome.

Methods: A total of 64 MPM patients treated with chemotherapy were enrolled in the study and longitudinally followed for changes in biomarker levels in response to treatment. Biomarkers levels were measured in serum using a human ELISA kit. Relative and absolute changes in biomarker levels were compared with the best radiological overall response at each time point.

Results: Median survival was 20.0 ± 2.4 (15.3-24.7) months in patients with partial and complete response, 17.0 ± 1.0 (15.0-19.0) months in patients with stable disease, and 9.0 ± 1.0 (7.0-11.0) months in patients with progressive disease. A significant decrease in serum levels of mesothelin, midkine, and HMGB1 was observed in patients with radiologically partial and complete responses to chemotherapy (p< 0.001, p= 0.016, and p= 0.039, respectively). In these patients, mesothelin levels decreased by 15%, midkine levels by 7%, and HMGB1 levels by 15%. In addition, HMGB1 serum levels were found to significantly increase by 15% in patients with radiologically progressive responses to chemotherapy compared to pretreatment serum levels (p= 0.035). In patients with partial and complete response to chemotherapy, mesothelin levels increased by 15%, midkine by 12%, and sestrin1 by 8% when the disease recurred (p= 0.004, p= 0.004 and p= 0.044, respectively).

Conclusion: Biomarkers may be useful in the longitudinal monitoring of response to treatment in MPM. However, the results of our study should be validated in larger groups with sufficient case numbers from multicenter institutions.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

利用生物标志物对恶性胸膜间皮瘤患者化疗反应的纵向监测。

背景:本研究的目的是对恶性胸膜间皮瘤(MPM)患者化疗前后及复发时血清间皮素、凝血素1、透明质酸合酶2 (HAS2)、midkine和高迁移率组盒1 (HMGB1)水平进行纵向调查，并比较生物标志物水平的变化与放射治疗结果。方法:共纳入64例接受化疗的MPM患者，并对治疗后生物标志物水平的变化进行纵向随访。使用人ELISA试剂盒测定血清中生物标志物水平。将生物标志物水平的相对和绝对变化与每个时间点的最佳放射学总体反应进行比较。结果:部分缓解和完全缓解患者的中位生存期为20.0±2.4(15.3-24.7)个月，疾病稳定患者的中位生存期为17.0±1.0(15.0-19.0)个月，疾病进展患者的中位生存期为9.0±1.0(7.0-11.0)个月。化疗放射学部分缓解和完全缓解的患者血清间皮素、midkine和HMGB1水平显著降低(p< 0.001, p= 0.016和p= 0.039)。在这些患者中，间皮素水平下降了15%，中间因子水平下降了7%，HMGB1水平下降了15%。此外，与化疗前相比，放射学进展性化疗患者血清HMGB1水平显著升高15% (p= 0.035)。在对化疗有部分和完全反应的患者中，疾病复发时间皮素水平升高15%，midkine升高12%，sestrin1升高8% (p= 0.004, p= 0.004和p= 0.044)。结论:生物标志物可用于MPM治疗反应的纵向监测。然而，我们的研究结果应该在更大的群体中得到验证，这些群体中有来自多中心机构的足够病例数。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊